Next |
home / stock / enta / enta message board
Subject | By | Source | When |
---|---|---|---|
Investing in biotech can be risky so you | vinmantoo | investorshub | 05/09/2023 4:25:54 PM |
Vin, its good. Stay optimistic. | Jake2234 | investorshub | 05/09/2023 12:43:10 PM |
The after hours trades means lots of pain | vinmantoo | investorshub | 05/09/2023 5:15:17 AM |
Yeah the market just tanked this thing and | Jake2234 | investorshub | 05/09/2023 1:10:04 AM |
My agenda is to speak the truth. | vinmantoo | investorshub | 05/09/2023 12:33:11 AM |
Now you are coming around! Great job. | Jake2234 | investorshub | 05/08/2023 11:31:56 PM |
Well, you deny that your bullish thesis was | vinmantoo | investorshub | 05/08/2023 11:04:10 PM |
My agenda is to speak the truth. Anyone | Jake2234 | investorshub | 05/08/2023 11:01:05 PM |
Well, you deny that your bullish thesis was | Jake2234 | investorshub | 05/08/2023 9:49:31 PM |
EDP-235 phase-2 slide set: | DewDiligence | investorshub | 05/08/2023 9:37:07 PM |
Now you deny. | vinmantoo | investorshub | 05/08/2023 9:28:45 PM |
Now you deny. Wow. Buying more shares for | Jake2234 | investorshub | 05/08/2023 9:22:38 PM |
Now trading at $24. I suppose your opinion | vinmantoo | investorshub | 05/08/2023 9:21:07 PM |
$ENTAIt looks like the 400mg (higher) dose will | DewDiligence | investorshub | 05/08/2023 9:03:38 PM |
Now trading at $24. I suppose your opinion | Jake2234 | investorshub | 05/08/2023 8:43:57 PM |
Key secondary endpoints evaluating virologic effect were not | Jake2234 | investorshub | 05/08/2023 8:32:12 PM |
$ENTA FY2Q23* financials3/31/23 pro forma cash=$454M : | DewDiligence | investorshub | 05/08/2023 8:20:30 PM |
$ENTA reports phase-2 data for EDP-235: | DewDiligence | investorshub | 05/08/2023 8:08:52 PM |
$ENTA what do you make of this data? | vinmantoo | investorshub | 05/06/2023 11:32:12 AM |
$ENTA where is the squeeze? | willyw | investorshub | 05/03/2023 4:22:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
2024-03-22 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product S...
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candida...